[Skip to Content]
[Skip to Content Landing]
July 4, 1990

The Role of Data Audits in Detecting Scientific Misconduct-Reply

Author Affiliations

Bolar Pharmaceutical Co, Inc Copiague, NY

Bolar Pharmaceutical Co, Inc Copiague, NY

JAMA. 1990;264(1):38. doi:10.1001/jama.1990.03450010039025

In Reply.—  Dr Rosenberg's letter propagates the lack of scientific and clinical objectivity as depicted in the original report.1Dr Rosenberg states in his letter, "Success with any agent is frequently rather fleeting. An anticonvulsant regimen that works on one occasion may certainly fail 3 months later. The need for reassessment and alterations in anticonvulsant regimens in these patients is well-known. Therefore, a Mysoline failure in January 1986 has little to do with the fact that in October 1985 Mysoline was effective, whereas generic primidone was not."I agree with Dr Rosenberg. However, is it not possible that what happened with Mysoline could also have happened with the generic? In fact, several patients were receiving generic primidone (Bolar) at the same time and did not experience increased seizures. Were there patients who were successful with the generic and not Mysoline?Dr Rosenberg should realize that a case report should